Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927472 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
A Phase 3 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
NCT00927472: Completed Phase 3 study, sponsored by Sun Pharmaceutical Industries.
NCT00927472 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 254 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00927472, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
Study Summary
In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
Primary Outcome
Treatment Success was evaluated using the Efficacy Intention to Treat (eITT) (LOCF) Efficacy ITT (eITT) was considered definitive. The primary efficacy variable was the proportion of index subjects who were considered a Treatment Success 14 days after their last treatment (Day 14 visit if only treated on Day 1, Day 21 visit if treated on Day 1 and Day 7). Index subject: 95 from 254 randomized (the youngest subject in the household who met index case criteria( having nits and at least 3 live li
Interventions
- DRUG Malathion gel 0.5%
- DRUG Permethrin 1% rinse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00927472 record still lists
NCT00927472 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Malathion gel 0.5% is the first listed.
NCT00927472 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00927472 about?
NCT00927472 is a clinical study titled "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice". In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years...
What is the current status of trial NCT00927472?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2009-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00927472?
The interventions under investigation include: Malathion gel 0.5% (DRUG), Permethrin 1% rinse (DRUG).
Who is sponsoring clinical trial NCT00927472?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00927472's enrollment target sits among peer trials
254 1245th of 2000 higher than 755 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia